Intellia Therapeutics Inc 2025年季度报告

For the quarterly period endedSeptember 30,2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromtoCommission File Number:001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) 36-4785571(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 40 Erie Street,Suite 130,Cambridge,Massachusetts02139(Address of principal executive offices)(Zip Code) 857-285-6200(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ The number of shares outstanding of the registrant’s common stock as of October 31, 2025:115,829,926shares. PART I - FINANCIAL INFORMATION Item 1. Financial Statements (unaudited)Condensed Consolidated Balance Sheets as of September 30, 2025and December 31, 20243Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months EndedSeptember 30, 2025 and 20244Condensed Consolidated Statements of Stockholders’ Equity for the Nine Months Ended September 30, 2025 and 20245Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 20246Notes to Condensed Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations22Item 3. Quantitative and Qualitative Disclosures About Market Risk32Item 4. Controls and Procedures.33PART II - OTHER INFORMATIONItem 1. Legal Proceedings33Item 1A. Risk Factors34Item 2. Unregistered Sales of Equity Securities and Use of Proceeds79Item 5. Other Information79Item 6. Exhibits80Signatures82 INTELLIA THERAPEUTICS, INC.Condensed Consolidated BalanceSheets (unaudited)(Amounts in thousands except share and per share data) INTELLIA THERAPEUTICS, INC.Condensed Consolidated Statements ofCash Flows (unaudited)(Amounts in thousands) INTELLIA THERAPEUTICS, INC.Notes to Condensed Consolidated FinancialStatements (unaudited) 1. Overview and Basis of Presentation IntelliaTherapeutics,Inc.(“Intellia”or the“Company”)is a leading clinical-stage gene editing company,focused onrevolutionizing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred toas CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Since its inception,Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmetmedical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical developmentexperience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of geneediting, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Tofully realize the transformative potential of CRISPR-based technologies, the Company is building a full-spectrum gene editingcompany, by leveraging its modular platform, to advancein vivoandex vivotherapies for diseases with high unmet need bypursuing two primary approaches. Forin vivoapplications to address genetic diseases, the Company deploys CRISPR as thetherapy. The Company’sin vivoprograms use CRISPR to enable precise editing of disease-causing genes directly inside the humanbody. In addition, the Company is advancingex vivoapplications to address immuno-oncology and autoimmune diseases, whe